FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating p...See more
Headquarters:
Japan
Company Type:
SME
Company size:
11-50 Employees
Year Founded:
2018 (7 years)
Address:
村岡東二丁目26番地の1; 藤沢市, 神奈川県 251-0012, JP
LOW
spending power
